mutation class

Small Mutation

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)

1 site for NCT05104567

HRAS Mutation, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +3 more conditions

cetuximab, +2 more drugs

immunotherapy, +1 more type

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

1 site for NCT04853043

APC Mutation, +4 more biomarkers

Colorectal Adenocarcinoma

cetuximab

targeted therapy

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

9 sites for NCT05039177

BRAF V600E, +2 more biomarkers

Colorectal Carcinoma

cetuximab, +3 more drugs

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

binimetinib

NRAS Mutation

Melanoma

Metastatic, +1 more state

Subsequent line

binimetinib

targeted therapy

cobimetinib

ARAF Mutation, +6 more biomarkers

Erdheim-Chester Disease, +2 more conditions

First line, +1 more context

cobimetinib

targeted therapy

trametinib

ARAF Mutation, +6 more biomarkers

Erdheim-Chester Disease, +2 more conditions

First line, +1 more context

trametinib

targeted therapy